# Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

> **NCT05905068** · PHASE1 · COMPLETED · sponsor: **Ikaria Bioscience Pty Ltd** · enrollment: 32 (actual)

## Conditions studied

- To Reduce the LDL-C Level in Hypercholesteremia Adult Patients
- Combination for Subgroup High LDL-c Patients With Other Comorbidities

## Interventions

- **DRUG:** RN0191 INJECTION

## Key facts

- **NCT ID:** NCT05905068
- **Lead sponsor:** Ikaria Bioscience Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-14
- **Primary completion:** 2024-02-24
- **Final completion:** 2024-05-14
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905068, "Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05905068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*